2 results
Approved WMOCompleted
The objective of this study is to evaluate the effect of the 4 successive monthly subcutaneous administrations of 30 mg of gevokizumab (in part A) , as well as 60mg (in part B) of the protocol, versus placebo on the reduction of arterial wall…
Approved WMOCompleted
The primary objective is:1. to compare the biodistribution and uptake in DLBCL of 89Zirconium (89Zr)-ofatumumab and 89Zr-rituximab (visual and quantitative).The secondary objectives are: 1. to compare the biodistribution and uptake in DLBCL of 89Zr-…